Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer

Autor: O'Byrne Kenneth J, Kay Elaine, Cummins Robert, Gately Kathy, Cathcart Mary-Clare, Pidgeon Graham P

Publikováno v: Molecular Cancer, Vol 10, Iss 1, p 25 (2011)

Abstract Background Thromboxane synthase (TXS) metabolises prostaglandin H2 into thromboxanes, which are biologically active on cancer cells. TXS over-expression has been reported in a range of cancers, and associated with a poor prognosis. TXS inhib

Externí odkaz: https://doaj.org/article/87015f59ff8a4d7e82518a1333d626f6

Occupational Injustice and the Right to Play: A Systematic Review of Accessible Playgrounds for Children With Disabilities.

Autor: Gately KA; Kelsey A. Gately, BA, is OTD Student, Department of Occupational Therapy, Johnson & Wales University, Providence, RI; kelseygately@gmail.com., Zawadzki AH; Anna H. Zawadzki, BS, is OTD Student, Department of Occupational Therapy, Johnson & Wales University, Providence, RI., Mosley AM; Alyssia M. Mosley, BS, is OTD Student, Department of Occupational Therapy, Johnson & Wales University, Providence, RI., Badua AK; Alyssamarie K. Badua, BS, is OTD Student, Department of Occupational Therapy, Johnson & Wales University, Providence, RI., Swanberg JE; Jennifer E. Swanberg, PhD, MMHS, OTR/L, is Professor, Department of Health Science, Johnson & Wales University, Providence, RI., Rosenthal SR; Samantha R. Rosenthal, PhD, MPH, is Associate Professor, Department of Health Science, Johnson & Wales University, Providence, RI.

Publikováno v: The American journal of occupational therapy : official publication of the American Occupational Therapy Association [Am J Occup Ther] 2023 Mar 01; Vol. 77 (2).

Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.

Autor: Collins DM; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland. denis.collins@dcu.ie., Madden SF; RCSI Division of Population Health Sciences, Royal College of Surgeons in Ireland, Beaux Lane House, Dublin, Ireland., Gaynor N; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland., AlSultan D; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland.; RCSI Division of Population Health Sciences, Royal College of Surgeons in Ireland, Beaux Lane House, Dublin, Ireland., Le Gal M; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland., Eustace AJ; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland., Gately KA; Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland., Hughes C; Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland., Davies AM; Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland., Mahgoub T; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland., Ballot J; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland., Toomey S; RCSI Molecular Medicine, Royal College of Surgeons in Ireland, RCSI Education & Research Centre, Beaumont Hospital, Beaumont, Dublin, Ireland., O'Connor DP; Royal College of Surgeons in Ireland, School of Pharmacy & Biomolecular Science, Dublin, Ireland., Gallagher WM; UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland., Holmes FA; Texas Oncology-Memorial Hermann Memorial City, US Oncology Research, Houston, -Texas., Espina V; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia., Liotta L; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia., Hennessy BT; RCSI Molecular Medicine, Royal College of Surgeons in Ireland, RCSI Education & Research Centre, Beaumont Hospital, Beaumont, Dublin, Ireland.; Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland., O'Byrne KJ; Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Queensland, Australia., Hasmann M; Roche Innovation Center Penzberg, Roche Diagnostics GmbH, Penzberg, Germany., Bossenmaier B; Pieris Pharmaceuticals, Inc., Boston, Massachusetts., O'Donovan N; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland., Crown J; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland.; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Feb 01; Vol. 27 (3), pp. 807-818. Date of Electronic Publication: 2020 Oct 29.

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.

Autor: Luszczak S; Molecular Diagnostics and Therapeutics Group, University College London, London, UK., Simpson BS; Molecular Diagnostics and Therapeutics Group, University College London, London, UK., Stopka-Farooqui U; Molecular Diagnostics and Therapeutics Group, University College London, London, UK., Sathyadevan VK; Molecular Diagnostics and Therapeutics Group, University College London, London, UK., Echeverria LMC; Molecular Diagnostics and Therapeutics Group, University College London, London, UK., Kumar C; Molecular Diagnostics and Therapeutics Group, University College London, London, UK., Costa H; Research Department of Pathology, University College London, London, UK., Haider A; Research Department of Pathology, University College London, London, UK., Freeman A; Research Department of Pathology, University College London, London, UK., Jameson C; Research Department of Pathology, University College London, London, UK., Ratynska M; Research Department of Pathology, University College London, London, UK., Ben-Salha I; Research Department of Pathology, University College London, London, UK., Sridhar A; Department of Uro-Oncology, UCLH NHS Foundation Trust, London, UK., Shaw G; Department of Uro-Oncology, UCLH NHS Foundation Trust, London, UK., Kelly JD; Department of Uro-Oncology, UCLH NHS Foundation Trust, London, UK., Pye H; Molecular Diagnostics and Therapeutics Group, University College London, London, UK., Gately KA; Trinity Translational Medicine Institute, St. James's Hospital Dublin, Dublin 8, Ireland., Whitaker HC; Molecular Diagnostics and Therapeutics Group, University College London, London, UK., Heavey S; Molecular Diagnostics and Therapeutics Group, University College London, London, UK. s.heavey@ucl.ac.uk.

Publikováno v: Scientific reports [Sci Rep] 2020 Sep 01; Vol. 10 (1), pp. 14380. Date of Electronic Publication: 2020 Sep 01.

Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.

Autor: Ryan SL; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia., Beard S; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia., Barr MP; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland., Umezawa K; Department of Molecular Target Medicine, Aichi Medical University, Nagakute, Japan., Heavey S; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; Division of Surgery and Interventional Sciences, University College London, United Kingdom., Godwin P; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland., Gray SG; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland., Cormican D; Department of Histopathology and Morbid Anatomy, School of Medicine, Trinity College Dublin, Dublin, Ireland., Finn SP; Department of Histopathology and Morbid Anatomy, School of Medicine, Trinity College Dublin, Dublin, Ireland; Department of Histopathology, Labmed Directorate, St. James's Hospital, Dublin, Ireland., Gately KA; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland., Davies AM; Vale Life Sciences Pty., Translational Research Institute, Brisbane, Australia., Thompson EW; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia., Richard DJ; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia., O'Byrne KJ; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia; Princess Alexandra Hospital, Brisbane, Australia., Adams MN; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia. Electronic address: mn.adams@qut.edu.au., Baird AM; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland. Electronic address: bairda@tcd.ie.

Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2019 Sep; Vol. 135, pp. 217-227. Date of Electronic Publication: 2019 Jul 12.